Skip to main content
SpringerLink
Log in

Effects of NAD at purine receptors in isolated blood vessels

  • Original Article
  • Published:
Purinergic Signalling Aims and scope Submit manuscript

Abstract

Nicotinamide adenine dinucleotide (NAD) belongs to the family of naturally occurring adenine dinucleotides, best known for their various intracellular roles. However, there is evidence that they can also be released from cells to act as novel extracellular signalling molecules. Relatively little is known about the extracellular actions of NAD, especially in the cardiovascular system. The present study investigated the actions of NAD in the rat thoracic aorta, porcine coronary artery and porcine mesenteric arteries, mounted in organ baths for isometric tension recording. In the rat thoracic aorta and porcine coronary artery, NAD caused endothelium-independent concentration-dependent vasorelaxations which were unaffected by palmitoylCoA, a P2Y1 receptor antagonist, but which were blocked by CGS15943, a non-selective adenosine receptor antagonist. In the porcine coronary artery, NAD-evoked relaxations were abolished by SCH58261, a selective A2A receptor antagonist. In the rat thoracic aorta, NAD-evoked relaxations were attenuated by A2A receptor antagonism with SCH58261 but were unaffected by an A2B receptor antagonist, MRS1754. In contrast, in the porcine mesenteric artery, NAD-evoked endothelium-independent contractions, which were unaffected by a P2 receptor antagonist, suramin, or by NF449, a P2X1 receptor antagonist, but were attenuated following P2X receptor desensitisation with αβ-meATP. In conclusion, the present results show that NAD can alter vascular tone through actions at purine receptors in three different arteries from two species; its molecular targets differ according to the type of blood vessel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492

    CAS  PubMed  Google Scholar 

  2. Ralevic V (2009) Purines as neurotransmitters and neuromodulators in blood vessels. Curr Vasc Pharmacol 7(1):3–14

    Article  CAS  PubMed  Google Scholar 

  3. Burnstock G, Ralevic V (2014) Purinergic signaling and blood vessels in health and disease. Pharmacol Rev 66(1):102–192

    Article  PubMed  Google Scholar 

  4. Ralevic V (2012) P2X receptors in the cardiovascular system. WIREs Membr Transp Signal 1(5):663–674

    Article  CAS  Google Scholar 

  5. Ziegler M (2000) New functions of a long-known molecule emerging roles of NAD in cellular signaling. Eur J Biochem 267(6):1550–1564

    Article  CAS  PubMed  Google Scholar 

  6. Ziegler M (2005) A vital link between energy and signal transduction. FEBS J 272(18):4561–4564

    Article  CAS  PubMed  Google Scholar 

  7. Lee HC (2001) Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol 41:317–345

    Article  PubMed  Google Scholar 

  8. Smyth LM, Bobalova J, Mendoza MG, Lew C, Mutafova-Yambolieva VN (2004) Release of β-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder. J Biol Chem 279(47):48893–48903

  9. Breen LT, Smyth LM, Yambolieva IA, Mutafova-Yambolieva VN, (2006) β-NAD is a novel nucleotide released on stimulation of nerve terminals in human urinary bladder detrusor muscle. Am J Physiol Renal Physiol 290(2):F486–95

  10. Mutafova-Yambolieva VN, Hwang SJ, Hao X, Chen H, Zhu MX, Wood JD, Ward SM, Sanders KM (2007) β-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci U S A 104(41):16359–16364

  11. Mutafova-Yambolieva VN (2012) Neuronal and extraneuronal release of ATP and NAD+ in smooth muscle. IUBMB Life 64(10):817–824

  12. De Flora A, Zocchi E, Guida L, Franco L, Bruzzone S (2004) Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADP-ribose system. Ann N Y Acad Sci 1028:176–191

  13. Bruzzone S, Guida L, Zocchi E, Franco L, De Flora A (2001) Connexin 43 hemichannels mediate Ca2+-regulated transmembrane NAD fluxes in intact cells. FASEB J 15(1):10–12

  14. Romanello M, Bicego M, Pirulli D, Crovella S, Moro L, D’Andrea P (2002) Extracellular NAD+: a novel autocrine/paracrine signal in osteoblast physiology. Biochem Biophys Res Commun 299(3):424–431

  15. Nikiforov A, Dölle C, Niere M, Ziegler M (2011) Pathways and subcellular compartmentation of NAD biosynthesis in human cells: From entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 286(24):21767–21778

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Burnstock G, Hoyle CH (1985) Actions of adenine dinucleotides in the guinea-pig taenia coli: NAD acts indirectly on P1-purinoceptors; NADP acts like a P2-purinoceptor agonist. Br J Pharmacol 84(4):825–831

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Hoyle CH (1990) Pharmacological activity of adenine dinucleotides in the periphery: possible receptor classes and transmitter function. Gen Pharmacol 21(6):827–831

    Article  CAS  PubMed  Google Scholar 

  18. Ralevic V, Hoyle CH, Burnstock G (1995) Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. J Physiol 483(Pt 3):703–713

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Cosker F, Cheviron N, Yamasaki M, Menteyne A, Lund FE, Moutin MJ, Galione A, Cancela JM (2010) The ecto-enzyme CD38 is a nicotinic acid adenine dinucleotide phosphate (NAADP) synthase that couples receptor activation to Ca2+ mobilization from lysosomes in pancreatic acinar cells. J Biol Chem 285(49):38251–38259

  20. Berthelier V, Tixier JM, Muller-Steffner H, Schuber F, Deterre P (1998) Human CD38 is an authentic NAP(P)+ glycohydrolase. Biochem J 330(Pt 3):1383–1390

  21. Moreschi I, Bruzzone S, Nicholas RA, Fruscione F, Sturla L, Benvenuto F, Usai C, Meis S, Kassack MU, Zocchi E, De Flora A (2006) Extracellular NAD+ is an agonist of the human P2Y1 purinergic receptor in human granulocytes. J Biol Chem 281(42):31419–31429

  22. Grahnert A, Klein C, Hauschildt S (2009) Involvement of P2X receptors in the NAD+-induced rise in [Ca2+]i in human monocytes. Purinergic Signal 5(3):309–319

  23. Alefishat E, Alexander SP, Ralevic V (2013) Antagonism of P2Y1-induced vasorelaxation by acyl CoA: a critical role for palmitate and 3′-phosphate. Br J Pharmacol 168(8):1911–1922

  24. Hansmann G, Bültmann R, Tuluc F, Starke K (1997) Characterization by antagonists of P2-receptors mediating endothelium-dependent relaxation in the rat aorta. Naunyn Schmiedebergs Arch Pharmacol 356(5):641–652

    Article  CAS  PubMed  Google Scholar 

  25. Rose’Meyer RB, Hope W (1990) Evidence that A2 purinoceptors are involved in endothelium-dependent relaxation of the rat thoracic aorta. Br J Pharmacol 100(3):576–580

  26. Balwierczak JL, Sharif R, Krulan CM, Field FP, Weiss GB, Miller MJ (1991) Comparative effects of a selective adenosine A2 receptor agonist, CGS 21680, and nitroprusside in vascular smooth muscle. Eur J Pharmacol 196(2):117–123

    Article  CAS  PubMed  Google Scholar 

  27. Merkel LA, Lappe RW, Rivera LM, Cox BF, Perrone MH (1992) Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther 260(2):437–443

  28. Monopoli A, Conti A, Zocchi C, Casati C, Volpini R, Cristalli G, Ongini E (1994) Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneimittelforschung 44(12):1296–1304

    CAS  PubMed  Google Scholar 

  29. Abebe W, Makujina SR, Mustafa SJ (1994) Adenosine receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium. Am J Physiol 266(5 Pt 2):H2018–H2025

    CAS  PubMed  Google Scholar 

  30. Olivecrona GK, Gotberg M, Harnek J, Wang L, Jacobson KA, Erlinge D (2004) Coronary artery reperfusion: the ADP receptor P2Y1 mediates early reactive hyperemia in vivo in pigs. Purinergic Signal 1(1):59–65

  31. Rayment SJ, Latif ML, Ralevic V, Alexander SPH (2007) Evidence for the expression of multiple uracil nucleotide-stimulated P2 receptors coupled to smooth muscle contraction in porcine isolated arteries. Br J Pharmacol 150(5):604–612

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Coddou C, Loyola G, Boyer JL, Bronfman M, Huidobro-Toro JP (2003) The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists. FEBS Lett 536(1–3):145–150

  33. Manolopoulos P, Glenn JR, Fox SC, May JA, Dovlatova NL, Tang SW, Thomas NR, Ralevic V, Heptinstall S (2008) Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Platelets 19(2):134–145

  34. Stone TW (1981) Actions of adenine dinucleotides on the vas deferens, guinea-pig taenia caeci and bladder. Eur J Pharmacol 75(2–3):93–102

    Article  CAS  PubMed  Google Scholar 

  35. Muller-Steffner HM, Malver O, Hosie L, Oppenheimer NJ, Schuber F (1992) Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of β-NAD+. J Biol Chem 267(14):9606–9611

  36. Shatarat, A., Dunn, W.R., Ralevic, V., Raised tone reveals ATP as a sympathetic neurotransmitter in the porcine mesenteric arterial bed. Purinergic Signalling, in press

  37. Gitterman DP, Evans RJ (2000) Properties of P2X and P2Y receptors are dependent on artery diameter in the rat mesenteric bed. Br J Pharmacol 131(8):1561–1568

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Judkins CP, Sobey CG, Dang TT, Miller AA, Dusting GJ, Drummond GR (2006) NADPH-induced contractions of mouse aorta do not involve NADPH oxidase: a role for P2X receptors. J Pharmacol Exp Ther 317(2):644–650

    Article  CAS  PubMed  Google Scholar 

  39. Sun L, Adebanjo OA, Moonga BS, Corisdeo S, Anandatheerthavarada HK, Biswas G, Arakawa T, Hakeda Y, Koval A, Sodam B, Bevis PJ, Moser AJ, Lai FA, Epstein S, Troen BR, Kumegawa M, Zaidi M (1999) CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption. J Cell Biol 146(5):1161–1172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Verderio C, Bruzzone S, Zocchi E, Fedele E, Schenk U, De Flora A, Matteoli M (2001) Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. J Neurochem 78(3):646–657

    Article  CAS  PubMed  Google Scholar 

  41. Esguerra M, Miller RF (2002) CD38 expression and NAD+-induced intracellular Ca2+ mobilization in isolated retinal Muller cells. Glia 39(3):314–319

    Article  PubMed  Google Scholar 

  42. Gerth A, Nieber K, Oppenheimer NJ, Hauschildt S (2004) Extracellular NAD+ regulates intracellular free calcium concentration in human monocytes. Biochem J 382(Pt 3):849–856

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Pfister M, Ogilvie A, da Silva CP, Grahnert A, Guse AH, Hauschildt S (2001) NAD degradation and regulation of CD38 expression by human monocytes/macrophages. Eur J Biochem 268(21):5601–5608

    Article  CAS  PubMed  Google Scholar 

  44. Gustafsson AJ, Muraro L, Dahlberg C, Migaud M, Chevallier O, Khanh HN, Krishnan K, Li N, Islam MS (2011) ADP ribose is an endogenous ligand for the purinergic P2Y1 receptor. Mol Cell Endocrinol 333(1):8–19

  45. Rubino A, Ralevic V, Burnstock G (1993) The P1-purinoceptors that mediate the prejunctional inhibitory effect of adenosine on capsaicin-sensitive nonadrenergic noncholinergic neurotransmission in the rat mesenteric arterial bed are of the A1 subtype. J Pharmacol Exp Ther 267(3):1100–1104

  46. Rubino A, Ralevic V, Burnstock G (1995) Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed. Br J Pharmacol 115(4):648–652

Download references

Acknowledgement

The support of the University of Jordan is gratefully acknowledged

Author information

Authors and Affiliations

  1. Department of Biopharmaceutics and Clinical Pharmacy Faculty of Pharmacy, University of Jordan, Amman, 11942, Jordan

    E. Alefishat

  2. School of Life Sciences Queen’s Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK

    S. P. H. Alexander & V. Ralevic

Authors
  1. E. Alefishat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. P. H. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Ralevic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Ralevic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alefishat, E., Alexander, S.P.H. & Ralevic, V. Effects of NAD at purine receptors in isolated blood vessels. Purinergic Signalling 11, 47–57 (2015). https://doi.org/10.1007/s11302-014-9428-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11302-014-9428-1

Keywords

Search

Navigation